A Phase 2b Randomised, Double Blind, Placebo-Controlled, Parallel Arm, Multi-Centre Study to Assess Efficacy and Safety of Multiple Dose Levels of AZD7594 DPI Given Once Daily for Twelve Weeks, Compared to Placebo, in Asthmatics Symptomatic on Low Dose ICS
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs AZD 7594 (Primary) ; Budesonide; Fluticasone furoate; Salbutamol
- Indications Asthma
- Focus Therapeutic Use
- Acronyms GRANIT
- Sponsors AstraZeneca
- 04 Feb 2019 Planned End Date changed from 6 Sep 2019 to 11 Nov 2019.
- 04 Feb 2019 Planned primary completion date changed from 6 Sep 2019 to 11 Nov 2019.
- 04 Feb 2019 Status changed from not yet recruiting to recruiting.